Small molecule agonists and antagonists of nr2f6 activity in animals

Abstract

The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.

1 . A method of increasing activity of a cell in an animal, comprising contacting the cell with a compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . A method of reducing the size of a tumor in an animal, comprising administering to the tumor a compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         3 . The method of  claim 2 , comprising the steps of:
 (a) extracting an amount of an animal's cellular material;   (b) isolating immune cells from the cellular material;   (c) activating the NR2F6 target in the isolated immune cells by binding them with the compound, or pharmaceutically acceptable salt thereof; and   (d) re-administering the isolated immune cells to the animal's body.   
     
     
         4 . The method of  claim 3 , wherein the animal's cellular material is blood. 
     
     
         5 . The method of  claim 3 , wherein the re-administering step comprises injection of the immune cells into the animal's body. 
     
     
         6 . A method of treating or reducing the effect of a reaction, disease or disorder, the method comprising activating the NR2F6 target in immune cells of an animal by contacting them with a compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         7 . The method of  claim 6 , wherein the reaction, disease or disorder comprises an autoimmune response. 
     
     
         8 . A method of treating a disorder in an animal comprising administering to a subject an effective amount of a compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         9 . The method of  claim 8 , wherein the disorder is cancer.